Recombinant Human KIR3DL3 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg4358

---

Validation Data Gallery

• 

  Purity of Recombinant Human KIR3DL3 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human KIR3DL3 protein Gln26-Leu322 (Accession# Q8N743) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 115653
• Accession: Q8N743
• PredictedSize: 58.3 kDa
• SDS-PAGE: 60-70 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

KIR3DL3, a member of the killer cell immunoglobulin-like receptor (KIR) family, is an inhibitory receptor primarily expressed on natural killer (NK) cells and a subset of CD8+ T cells. It plays a role in immune regulation by recognizing specific HLA class I molecules, contributing to the balance between immune activation and inhibition. Recent research has identified KIR3DL3 as an inhibitory receptor for HHLA2, a B7 family ligand, suggesting its involvement in immune checkpoint pathways. KIR3DL3's interaction with HHLA2 can recruit SHP-1 and SHP-2 to attenuate signaling pathways such as Vav1, ERK1/2, AKT, and NF-κB, thereby inhibiting CD8+ T and NK cell functions. It is expressed on immune cells infiltrating HHLA2+ tumors from the human kidney, lung, gallbladder, and stomach, suggesting its potential as a therapeutic target for cancer.

References:

1.Trundley AE. et al. (2006). Immunogenetics. 57(12):904-916.
2.Wei Y. et al. (2021). Sci Immunol. 6(61):eabf9792.
3.Campbell KS. (2021). Cancer Immunol Res. 9(2):128. 
4.Li Y. et al. (2023). J Adv Res. 47:137-150.